NGI-1, a reversible catalytic subunit inhibitor of the OST, has higher specificity for STT3B than for STT3A.26 Since EREG acts as a key driver of oncogenesis and survival signaling in HNSCC, we asked the biochemical consequences of OST inhibition on EREG function. The gene discussed is STT3A; the disease is head and neck squamous cell carcinoma.